Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Medically-Inoperable Non-Small Lung Cancer Patients

Official Title

A Randomized Trial of Medically-Inoperable Stage 1 Non-small Cell Lung Cancer Patients Comparing Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy

Summary:

A multi-centre randomized controlled open-label trial in medically inoperable patients with biopsy-proven early stage non-small cell lung cancer (NSCLC). Eligible and consenting patients will be randomly allocated to receive stereotactic body radiation therapy (SBRT) or conventional radiation therapy (CRT) in a 2:1 ratio. Radiation Therapy will be administered as soon as possible following randomization and subjects will be followed for 5 years post-randomization for cancer recurrence, toxicity and survival. The primary outcome is local control (LC). The trial will be conducted at 16-20 clinical centres throughout Canada.

Trial Description

Primary Outcome:

• Local Control

• Overall Survival
• Disease-Free Survival
• Event-Free Survival
• Lung Cancer-Specific Survival
• Radiation Treatment-Related Death
• Toxicity
• Quality of Life
• Cost-Utility

View this trial on ClinicalTrials.gov